Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifidobacterium infantis 35624 in female IBS
NCT00135031Phase 3Completed
- Sponsor
- Procter & Gamble
- Start
- Jan 2004
- Primary completion
- Sep 2004
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bifidobacterium infantis 35624 in irritable bowel syndrome (IBS) (4 arms), sponsored by Procter & Gamble. Primary endpoint: Abdominal pain score at 4 weeks. Started Jan 2004; status: completed.
02
Drugs
bifidobacterium infantis 35624
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT00135031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135031.